 This is a phase II trial with a parallel-group design, consisting of a drug-free run-in phase phase 1, followed by a placebo controlled double-blind phase phase 2. Patients will receive either R093877 0.5 mg b.i.d., 1 mg b.i.d. or 2 mg b.i.d. or placebo for a period of 12 weeks. 